Ventana Genetics Inc.
This article was originally published in Start Up
Executive Summary
Drug Target Discovery. Ventana is developing libraries of "perturbagens"; peptides which disrupt cellular processes by binding to proteins. Initially the firm will search for novel melanoma targets.